At the time of disposal, MAP was a technologically leading producer of medical instruments for the diagnosis and therapy of sleep-related respiratory diseases. MAP specifically focused on obstructive sleep apnoea and was the market leader in Europe in this segment.
During the ownership period of the GEP funds, the company underwent significant growth abroad. The focus in this context was the expansion of sales activities in France, Austria, Switzerland and the Netherlands, which were strengthened with the establishment of country-specific subsidiaries. Based on its technological leadership and the strong market position in Europe, MAP was sold to the publicly listed US company ResMed Inc. in 2001.